AstraZeneca and BMS submit Onglyza in EU and US
This article was originally published in Scrip
Executive Summary
AstraZenecaand Bristol-Myers Squibbhave submitted applications for EU and US approval of their investigational type 2 diabetes treatment Onglyza (saxagliptin), a dipeptidyl peptidase-4 (DPP-IV) inhibitor.